Showing 3991-4000 of 7034 results for "".
- CeraVe Research Highlights the Impact of UV Exposure on the Skin Barrier and the Benefits of Ceramideshttps://practicaldermatology.com/news/cerave-research-highlights-the-impact-of-uv-exposure-on-the-skin-barrier-and-the-benefits-of-ceramides/2460859/A skincare regimen that includes a moisturizer and sunscreen formulated with ceramides can help protect against ultraviolet(UV)-induced skin barrier damage and improve skin barrier health overall, according to new research in the Journal of Drugs in Dermatology. The clin
- Hoth Therapeutics, Inc.’s BioLexa in AD: So Far, So Safehttps://practicaldermatology.com/news/hoth-therapeutics-incs-biolexa-in-ad-so-far-so-safe/2460853/Hoth Therapeutics, Inc.’s BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed, according to the safety results in Cohort 1 of its first in human clinical trial of the BioLexa platform to treat atopic dermatitis.
- European Commission Approves Libtayo as First Immunotherapy for Patients with Advanced BCChttps://practicaldermatology.com/news/european-commission-approves-libtayo-as-first-immunotherapy-for-patients-with-advanced-bcc/2460851/The PD-1 inhibitor Libtayo® (cemiplimab, Regeneron/Sanofi) is approved by the European Commission to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI). Libtayo is now approved for thr
- Research Brief: Personalized Bacteriotherapy May Improve Skin Microbiome and Symptoms in ADhttps://practicaldermatology.com/news/research-brief-personalized-bacteriotherapy-may-improve-skin-microbiome-and-symptoms-in-ad/2460841/Bacteriotherapy with an autologous strain of bacteria may safely improve S. aureus colonization in the microbiome of patients with atopic dermatitis (AD) and improve disease severity, a
- FDA Approves StrataGraft for the Treatment of Adults with Thermal Burnshttps://practicaldermatology.com/news/fda-approves-stratagraft-for-the-treatment-of-adults-with-thermal-burns/2460839/The U.S. Food and Drug Administration approved StrataGraft for the treatment of adult deep partial thickness burns. "Serious burns can be an incredibly difficult injury to treat and can adversely affect more than just the skin. The goal of burn management is to help the patient ret
- CellFX from Pulse Biosciences Cleared in Canadahttps://practicaldermatology.com/news/cellfx-from-pulse-biosciences-cleared-in-canada/2460833/The CellFX® System from Pulse Biosciences is now approved via a Medical Device License from Health Canada for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. Puls
- FDA Approves Expanded Use of the RECELL System for Extensive Burns and Pediatric Patientshttps://practicaldermatology.com/news/fda-approves-expanded-use-of-the-recell-system-for-extensive-burns-and-pediatric-patients/2460831/The U.S. Food and Drug Administration (FDA) approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients. Specifically, RECELL is now in
- FDA Grants Breakthrough Device Status to Alpha DaRT for SCChttps://practicaldermatology.com/news/fda-grants-breakthrough-device-status-to-alpha-dart-for-scc/2460829/The U.S. Food and Drug Administration (FDA) granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma (SCC) of the skin and oral cavity without curative standard of care. Alpha Tau submitted data to the FDA supporting this de
- Allergan Aesthetics, Botox Cosmetic Unveil "See Yourself" Campaign with Real Stories from Real Patientshttps://practicaldermatology.com/news/allergan-aesthetics-botox-cosmetic-unveil-see-yourself-campaign-with-real-stories-from-real-patients/2460828/Allergan Aesthetics is launching "See Yourself," a new campaign featuring documentary-style shorts that tell the stories of real Botox Cosmetic patients. Watch 'See Yourself' shorts at www.BotoxCosmetic.com and @Bot
- EULAR: Data Show Benefit of Tremfya in PsA After Anti-TNF Failurehttps://practicaldermatology.com/news/eular-day-shown-benefit-of-tremfya-in-psa-after-anti-tnf-failure/2460834/New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Trem